董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Claire Pomeroy | 女 | Independent Director | 68 | 27.00万美元 | 未持股 | 2023-06-16 |
| Christopher Simon | 男 | President and Chief Executive Officer,Director | 59 | 1068.64万美元 | 未持股 | 2023-06-16 |
| Lloyd E. Johnson | 男 | Independent Director | 69 | 27.30万美元 | 未持股 | 2023-06-16 |
| Robert Abernathy | 男 | Independent Director | 68 | 28.50万美元 | 未持股 | 2023-06-16 |
| Ellen M. Zane | 女 | Independent Director,Chair of the Board | 71 | 44.00万美元 | 未持股 | 2023-06-16 |
| Charles J. Dockendorff | 男 | Independent Director | 68 | 29.30万美元 | 未持股 | 2023-06-16 |
| Mark W. Kroll | 男 | Independent Director | 70 | 27.00万美元 | 未持股 | 2023-06-16 |
| Michael J. Coyle | 男 | Independent Director | 61 | 27.30万美元 | 未持股 | 2023-06-16 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| James C. D'Arecca | 男 | Executive Vice President, Chief Financial Officer | 52 | 376.47万美元 | 未持股 | 2023-06-16 |
| Christopher Simon | 男 | President and Chief Executive Officer,Director | 59 | 1068.64万美元 | 未持股 | 2023-06-16 |
| Michelle Basil | 女 | Executive Vice President, General Counsel | 51 | 299.04万美元 | 未持股 | 2023-06-16 |
| Anila Lingamneni | 女 | Executive Vice President, Chief Technology Officer | 56 | 232.63万美元 | 未持股 | 2023-06-16 |
| Josep L. Llorens | 男 | Senior Vice President, Global Manufacturing and Supply Chain | 61 | 234.47万美元 | 未持股 | 2023-06-16 |
| Roy Galvin | 男 | President, Global Plasma and Blood Center | 54 | 未披露 | 未持股 | 2023-06-16 |
| Laurie A. Miller | 女 | Senior Vice President, Chief Human Resources Officer | 50 | 未披露 | 未持股 | 2023-06-16 |
| Stewart W. Strong | 男 | President, Global Hospital | 56 | 未披露 | 未持股 | 2023-06-16 |
董事简历
中英对照 | 中文 | 英文- Claire Pomeroy
-
Claire Pomeroy，2014年以来，她一直担任董事。2013年以来，她一直担任the Albert and Mary Lasker Foundation（私人基金会，通过识别研究人才、公众教育和宣传加快对医学研究的支持来改善健康）的总裁。之前，她担任院长加州大学戴维斯分校（University of California, Davis，UC Davis）医学院院长和加州大学戴维斯分校卫生系统（ UC Davis Health System）首席执行官。她是Expanesthetics, Inc.和the Sierra Health Foundation。的董事会成员。她是Morehouse School of Medicine的信托董事会和the Foundation for Biomedical Research董事成员。
Claire Pomeroy,has served since 2013 as President of the Albert and Mary Lasker Foundation, a private foundation that seeks to improve health by accelerating support for medical research through recognition of research excellence, public education and advocacy. Prior thereto, she served as Dean and Vice Chancellor of the University of California, Davis School of Medicine. She is an elected member of the National Academy of Medicine. Dr. Pomeroy is a member of the Board of Directors of Haemonetics Corporation (NYSE: HAE). Dr. Pomeroy also serves on the Board of Directors of the Sierra Health Foundation, Center for Women in Academic Medicine and Science, iBiology/Science Communication Lab, Science Philanthropy Alliance, Geisinger School of Medicine, and Morehouse School of Medicine. Dr. Pomeroy holds a Bachelor's degree in Biomedical Sciences and Doctor of Medicine (M.D.) from the University of Michigan, as well as a Master of Business Administration from the University of Kentucky. - Claire Pomeroy，2014年以来，她一直担任董事。2013年以来，她一直担任the Albert and Mary Lasker Foundation（私人基金会，通过识别研究人才、公众教育和宣传加快对医学研究的支持来改善健康）的总裁。之前，她担任院长加州大学戴维斯分校（University of California, Davis，UC Davis）医学院院长和加州大学戴维斯分校卫生系统（ UC Davis Health System）首席执行官。她是Expanesthetics, Inc.和the Sierra Health Foundation。的董事会成员。她是Morehouse School of Medicine的信托董事会和the Foundation for Biomedical Research董事成员。
- Claire Pomeroy,has served since 2013 as President of the Albert and Mary Lasker Foundation, a private foundation that seeks to improve health by accelerating support for medical research through recognition of research excellence, public education and advocacy. Prior thereto, she served as Dean and Vice Chancellor of the University of California, Davis School of Medicine. She is an elected member of the National Academy of Medicine. Dr. Pomeroy is a member of the Board of Directors of Haemonetics Corporation (NYSE: HAE). Dr. Pomeroy also serves on the Board of Directors of the Sierra Health Foundation, Center for Women in Academic Medicine and Science, iBiology/Science Communication Lab, Science Philanthropy Alliance, Geisinger School of Medicine, and Morehouse School of Medicine. Dr. Pomeroy holds a Bachelor's degree in Biomedical Sciences and Doctor of Medicine (M.D.) from the University of Michigan, as well as a Master of Business Administration from the University of Kentucky.
- Christopher Simon
-
Christopher Simon，担任总裁兼首席执行官，于2016年5月加入Haemonetics公司。他此前曾担任McKinsey & Company的高级合伙人，从事全球医疗产品实践。他曾担任McKinsey & Company的顾问（1993年以来），最近担任McKinsey & Company与Haemonetics的战略回顾的领导合伙人。此前，他曾担任Baxter Healthcare Corporation的商业职务。
Christopher Simon,is President and Chief Executive Officer of Haemonetics Corporation. He joined Haemonetics in May 2016 and Haemonetics Corporation Board in September 2016. Mr. Simon previously served as a Senior Partner of McKinsey & Company where he led the Global Medical Products Practice. Mr. Simon served as a consultant with McKinsey & Company beginning in 1993 and was the lead partner for McKinsey & Company's strategy review with Haemonetics that began in October 2015, where he gained invaluable insights into the Company's business and markets. Prior to his career at McKinsey & Company, Mr. Simon served in commercial roles with Baxter Healthcare Corporation and as a U.S. Army Infantry Officer in Korea with the 1st Ranger Battalion. He also currently serves on the Board of Directors of AdvaMed, a global trade association of companies that develop, produce, manufacture and market medical technologies. Mr. Simon earned a Bachelor of Science in Economics from the Wharton School at the University of Pennsylvania and an M.B.A. from Harvard Business School. - Christopher Simon，担任总裁兼首席执行官，于2016年5月加入Haemonetics公司。他此前曾担任McKinsey & Company的高级合伙人，从事全球医疗产品实践。他曾担任McKinsey & Company的顾问（1993年以来），最近担任McKinsey & Company与Haemonetics的战略回顾的领导合伙人。此前，他曾担任Baxter Healthcare Corporation的商业职务。
- Christopher Simon,is President and Chief Executive Officer of Haemonetics Corporation. He joined Haemonetics in May 2016 and Haemonetics Corporation Board in September 2016. Mr. Simon previously served as a Senior Partner of McKinsey & Company where he led the Global Medical Products Practice. Mr. Simon served as a consultant with McKinsey & Company beginning in 1993 and was the lead partner for McKinsey & Company's strategy review with Haemonetics that began in October 2015, where he gained invaluable insights into the Company's business and markets. Prior to his career at McKinsey & Company, Mr. Simon served in commercial roles with Baxter Healthcare Corporation and as a U.S. Army Infantry Officer in Korea with the 1st Ranger Battalion. He also currently serves on the Board of Directors of AdvaMed, a global trade association of companies that develop, produce, manufacture and market medical technologies. Mr. Simon earned a Bachelor of Science in Economics from the Wharton School at the University of Pennsylvania and an M.B.A. from Harvard Business School.
- Lloyd E. Johnson
-
LloydE.Johnson于2004年至2015年担任埃森哲公司（Accenture Corporation）的全球财务和内部审计总经理，埃森哲公司是一家全球管理咨询和专业服务公司，提供战略，咨询，数字技术和运营服务。加入Accenture Corporation之前，他曾担任Delphi Automotive plc（汽车零部件制造商）的执行董事、并购和总审计师（从1999年到2004年）。从1997年到1999年，他曾担任Emerson Electric Corporation（多元化的全球制造公司，服务于工业、商业和消费市场）的公司Vice President、财务和首席审计执行官。职业生涯早期，他曾担任Sara Lee Knit Products公司（Sara Lee Corporation的部门）、Shaw Food Industries公司（私人持有的食品服务供应公司）、Harper，Wiggins&Johnson公司（区域会计师事务所）的高级财务领导职务。Johnson先生在Coopers&Lybrand开始了他的职业生涯，该公司是一家全球会计师事务所，后来成为普华永道会计师事务所的一部分。
Lloyd E. Johnson,served as Global Managing Director, Finance and Internal Audit, for Accenture Corporation from 2004 to 2015. At Accenture, he was responsible for leading the global consulting company's corporate audit organization and providing guidance and counsel in finance and strategic planning. Prior to joining Accenture, Mr. Johnson was an Executive Director of M&A and General Auditor at Delphi Automotive and was Corporate Vice President, Finance and Chief Audit Executive at Emerson Electric Corporation. Mr. Johnson began his career at Coopers & Lybrand, which is now part of PwC. Mr. Johnson currently serves on the boards of Apogee Enterprises, Haemonetics Corporation, VSE Corporation and AARP.Mr. Johnson received a Bachelor of Science in Business Administration degree in accounting and a Master of Accountancy degree with a major in accounting from the University of South Carolina and his Master of Business Administration from Duke University. - LloydE.Johnson于2004年至2015年担任埃森哲公司（Accenture Corporation）的全球财务和内部审计总经理，埃森哲公司是一家全球管理咨询和专业服务公司，提供战略，咨询，数字技术和运营服务。加入Accenture Corporation之前，他曾担任Delphi Automotive plc（汽车零部件制造商）的执行董事、并购和总审计师（从1999年到2004年）。从1997年到1999年，他曾担任Emerson Electric Corporation（多元化的全球制造公司，服务于工业、商业和消费市场）的公司Vice President、财务和首席审计执行官。职业生涯早期，他曾担任Sara Lee Knit Products公司（Sara Lee Corporation的部门）、Shaw Food Industries公司（私人持有的食品服务供应公司）、Harper，Wiggins&Johnson公司（区域会计师事务所）的高级财务领导职务。Johnson先生在Coopers&Lybrand开始了他的职业生涯，该公司是一家全球会计师事务所，后来成为普华永道会计师事务所的一部分。
- Lloyd E. Johnson,served as Global Managing Director, Finance and Internal Audit, for Accenture Corporation from 2004 to 2015. At Accenture, he was responsible for leading the global consulting company's corporate audit organization and providing guidance and counsel in finance and strategic planning. Prior to joining Accenture, Mr. Johnson was an Executive Director of M&A and General Auditor at Delphi Automotive and was Corporate Vice President, Finance and Chief Audit Executive at Emerson Electric Corporation. Mr. Johnson began his career at Coopers & Lybrand, which is now part of PwC. Mr. Johnson currently serves on the boards of Apogee Enterprises, Haemonetics Corporation, VSE Corporation and AARP.Mr. Johnson received a Bachelor of Science in Business Administration degree in accounting and a Master of Accountancy degree with a major in accounting from the University of South Carolina and his Master of Business Administration from Duke University.
- Robert Abernathy
-
Robert Abernathy，Abernathy先生于2017年10月加入董事会，并担任薪酬委员会成员。Abernathy先生曾于2014年10月至2017年6月退休期间担任医疗技术公司Halyard Health Inc.（从金佰利（Kimberly-Clark）分拆而来）的董事长兼首席执行官。Abernathy先生于1982年加入金佰利公司（Kimberly-Clark），这是一家全球性的个人护理产品公司，并担任了越来越重要的职务，包括金佰利公司全球医疗保健业务总裁、发展中和新兴市场集团总裁、金佰利澳大利亚公司董事总经理以及North Atlantic消费品公司总裁。除了他目前的上市公司董事会服务，Abernathy先生此前曾担任Halyard Health，Inc.和RadioShack Corp.的董事。
Robert Abernathy,joined Haemonetics Corporation Board in October 2017 and is Chair of the Compensation Committee and a member of the Governance and Compliance Committee. Mr. Abernathy served as Chairman of the Board of Directors and Chief Executive Officer of Halyard Health Inc., a publicly-traded medical technology company and spin-off from Kimberly-Clark, from October 2014 until his retirement in June 2017 (he continued as Chairman until September 2017). Mr. Abernathy joined Kimberly-Clark, a global personal care products company, in 1982 and held numerous roles of increasing responsibility, including President of Kimberly-Clark's Global Health Care business, Group President, Developing & Emerging Markets, Managing Director, Kimberly-Clark Australia and President, North Atlantic Consumer Products. - Robert Abernathy，Abernathy先生于2017年10月加入董事会，并担任薪酬委员会成员。Abernathy先生曾于2014年10月至2017年6月退休期间担任医疗技术公司Halyard Health Inc.（从金佰利（Kimberly-Clark）分拆而来）的董事长兼首席执行官。Abernathy先生于1982年加入金佰利公司（Kimberly-Clark），这是一家全球性的个人护理产品公司，并担任了越来越重要的职务，包括金佰利公司全球医疗保健业务总裁、发展中和新兴市场集团总裁、金佰利澳大利亚公司董事总经理以及North Atlantic消费品公司总裁。除了他目前的上市公司董事会服务，Abernathy先生此前曾担任Halyard Health，Inc.和RadioShack Corp.的董事。
- Robert Abernathy,joined Haemonetics Corporation Board in October 2017 and is Chair of the Compensation Committee and a member of the Governance and Compliance Committee. Mr. Abernathy served as Chairman of the Board of Directors and Chief Executive Officer of Halyard Health Inc., a publicly-traded medical technology company and spin-off from Kimberly-Clark, from October 2014 until his retirement in June 2017 (he continued as Chairman until September 2017). Mr. Abernathy joined Kimberly-Clark, a global personal care products company, in 1982 and held numerous roles of increasing responsibility, including President of Kimberly-Clark's Global Health Care business, Group President, Developing & Emerging Markets, Managing Director, Kimberly-Clark Australia and President, North Atlantic Consumer Products.
- Ellen M. Zane
-
Ellen M. Zane，塔夫茨医学中心名誉首席执行官，塔夫茨医学创始主席。赞恩女士此前曾在2004年至2011年担任塔夫茨医疗中心总裁兼首席执行官，当时她从该职位退休。在此之前，Zane女士曾担任Mass General Brigham（前身为Partners Healthcare System）的网络总裁，这是一个由哈佛附属麻省总医院和Brigham and Women''s Hospital赞助的医生/医院网络。赞恩女士此前还曾担任马萨诸塞州昆西市昆西医院的首席执行官。Zane女士目前担任Savista的董事，Savista是一家总部位于格鲁吉亚的私营公司，涉及医疗保健收入周期管理；Fiduciary Trust Company，一家私营财富管理公司；以及AgNovos Healthcare，LLC，一家私营医疗设备公司，专注于骨骼健康。Zane女士现任Haemonetics Corporation和Synchrony Financial的董事，此前曾担任Azenta, Inc.、Century Capital Management、Parexel International Corporation、Lincare Holdings Inc.和Press Ganey控股的董事。赞恩女士获得了库里学院、斯通希尔学院、本特利大学和马萨诸塞大学达特茅斯分校的荣誉学位。赞恩女士在美国天主教大学获得听力学和言语语言病理学硕士学位，在乔治华盛顿大学获得学士学位。
Ellen M. Zane,is CEO Emeritus at Tufts Medical Center and Founding Chair at Tufts Medicine. Ms. Zane previously served as President and Chief Executive Officer of Tufts Medical Center from 2004 to 2011 when she retired from this role. Prior to this, Ms. Zane served as Network President for Mass General Brigham (formerly Partners Healthcare System), a physician/hospital network sponsored by the Harvard-affiliated Massachusetts General Hospital and Brigham and Women's Hospital. Ms. Zane also previously served as Chief Executive Officer of Quincy Hospital in Quincy, Massachusetts. Ms. Zane currently is a director of Savista, a Georgia-based private company involved with healthcare revenue cycle management; Fiduciary Trust Company, a privately owned wealth management company; and AgNovos Healthcare, LLC, a privately held medical device company, focused on bone health. Ms. Zane is currently a director of Haemonetics Corporation and Synchrony Financial and previously served as a director of Azenta, Inc., Century Capital Management, Parexel International Corporation, Lincare Holdings Inc. and Press Ganey Holdings. Ms. Zane has received Honorary Degrees from Curry College, Stonehill College, Bentley University and University of Massachusetts-Dartmouth. Ms. Zane received an MA in audiology and speech-language pathology from Catholic University of America and a BA from George Washington University. - Ellen M. Zane，塔夫茨医学中心名誉首席执行官，塔夫茨医学创始主席。赞恩女士此前曾在2004年至2011年担任塔夫茨医疗中心总裁兼首席执行官，当时她从该职位退休。在此之前，Zane女士曾担任Mass General Brigham（前身为Partners Healthcare System）的网络总裁，这是一个由哈佛附属麻省总医院和Brigham and Women''s Hospital赞助的医生/医院网络。赞恩女士此前还曾担任马萨诸塞州昆西市昆西医院的首席执行官。Zane女士目前担任Savista的董事，Savista是一家总部位于格鲁吉亚的私营公司，涉及医疗保健收入周期管理；Fiduciary Trust Company，一家私营财富管理公司；以及AgNovos Healthcare，LLC，一家私营医疗设备公司，专注于骨骼健康。Zane女士现任Haemonetics Corporation和Synchrony Financial的董事，此前曾担任Azenta, Inc.、Century Capital Management、Parexel International Corporation、Lincare Holdings Inc.和Press Ganey控股的董事。赞恩女士获得了库里学院、斯通希尔学院、本特利大学和马萨诸塞大学达特茅斯分校的荣誉学位。赞恩女士在美国天主教大学获得听力学和言语语言病理学硕士学位，在乔治华盛顿大学获得学士学位。
- Ellen M. Zane,is CEO Emeritus at Tufts Medical Center and Founding Chair at Tufts Medicine. Ms. Zane previously served as President and Chief Executive Officer of Tufts Medical Center from 2004 to 2011 when she retired from this role. Prior to this, Ms. Zane served as Network President for Mass General Brigham (formerly Partners Healthcare System), a physician/hospital network sponsored by the Harvard-affiliated Massachusetts General Hospital and Brigham and Women's Hospital. Ms. Zane also previously served as Chief Executive Officer of Quincy Hospital in Quincy, Massachusetts. Ms. Zane currently is a director of Savista, a Georgia-based private company involved with healthcare revenue cycle management; Fiduciary Trust Company, a privately owned wealth management company; and AgNovos Healthcare, LLC, a privately held medical device company, focused on bone health. Ms. Zane is currently a director of Haemonetics Corporation and Synchrony Financial and previously served as a director of Azenta, Inc., Century Capital Management, Parexel International Corporation, Lincare Holdings Inc. and Press Ganey Holdings. Ms. Zane has received Honorary Degrees from Curry College, Stonehill College, Bentley University and University of Massachusetts-Dartmouth. Ms. Zane received an MA in audiology and speech-language pathology from Catholic University of America and a BA from George Washington University.
- Charles J. Dockendorff
-
Charles J. Dockendorff，自2006年12月起成为Covidien的执行副总裁兼首席财务官。在此之前，从1995年10月到2006年11月他担任公司副总裁兼首席财务官。
Charles J. Dockendorff,served as the Executive Vice President and Chief Financial Officer of Covidien plc from 2006 until his retirement in March 2015, and as Vice President and Chief Financial Officer from 1995 to 2006. Mr. Dockendorff was appointed Chief Financial Officer of Tyco Healthcare in 1995, having joined the Kendall Healthcare Products Company as Controller. He was named Vice President and Controller of Kendall in 1994. Prior to joining Kendall/Tyco Healthcare, Mr. Dockendorff was the Chief Financial Officer, Vice President of Finance and Treasurer of Epsco Inc. and Infrared Industries, Inc. Mr. Dockendorff holds a Bachelor's degree in Business Administration and Accounting from the University of Massachusetts and a Master of Science degree in Finance from Bentley College. He currently serves on the board of directors of Boston Scientific Corporation, Haemonetics Corporation and Hologic, Inc.. Mr. Dockendorff self-identifies as a white male. - Charles J. Dockendorff，自2006年12月起成为Covidien的执行副总裁兼首席财务官。在此之前，从1995年10月到2006年11月他担任公司副总裁兼首席财务官。
- Charles J. Dockendorff,served as the Executive Vice President and Chief Financial Officer of Covidien plc from 2006 until his retirement in March 2015, and as Vice President and Chief Financial Officer from 1995 to 2006. Mr. Dockendorff was appointed Chief Financial Officer of Tyco Healthcare in 1995, having joined the Kendall Healthcare Products Company as Controller. He was named Vice President and Controller of Kendall in 1994. Prior to joining Kendall/Tyco Healthcare, Mr. Dockendorff was the Chief Financial Officer, Vice President of Finance and Treasurer of Epsco Inc. and Infrared Industries, Inc. Mr. Dockendorff holds a Bachelor's degree in Business Administration and Accounting from the University of Massachusetts and a Master of Science degree in Finance from Bentley College. He currently serves on the board of directors of Boston Scientific Corporation, Haemonetics Corporation and Hologic, Inc.. Mr. Dockendorff self-identifies as a white male.
- Mark W. Kroll
-
Mark W. Kroll，2003年起担任本公司董事。他于2005年从St. Jude Medical退休；1995年以来，他在该公司担任过多个行政职务，最近的是心律管理部门的高级副总裁、首席技术官。他在University of Minnesota获得数学学士学位、电气工程硕士和博士学位，在St. Thomas获得工商管理硕士学位。他拥有340多项已批准的美国专利，是以下机构的资深会员：American College of Cardiology、Heart Rhythm Society、Institute of Electronics and Electrical Engineering，和American Institute for Medicine and Biology in Engineering。他也是Haemonetics Corporation的董事。
Mark W. Kroll,retired in July 2005 from St. Jude Medical, Inc., where he held various executive level positions since 1995, most recently as Senior Vice President and Chief Technology Officer, Cardiac Rhythm Management Division. Dr. Kroll holds a B.S. in Mathematics and a M.S. and a Ph.D. from the Electrical Engineering department of the University of Minnesota and an M.B.A. from the University of St. Thomas. Dr. Kroll is also the named inventor of over 350 issued U.S. patents and is a Fellow of: American College of Cardiology, Heart Rhythm Society, Institute of Electronics and Electrical Engineering ("IEEE"), and the American Institute for Medicine and Biology in Engineering ("AIMBE"). Dr. Kroll has also served on the board of Haemonetics Corporation, provider of innovative medical technology solutions, since 2006. - Mark W. Kroll，2003年起担任本公司董事。他于2005年从St. Jude Medical退休；1995年以来，他在该公司担任过多个行政职务，最近的是心律管理部门的高级副总裁、首席技术官。他在University of Minnesota获得数学学士学位、电气工程硕士和博士学位，在St. Thomas获得工商管理硕士学位。他拥有340多项已批准的美国专利，是以下机构的资深会员：American College of Cardiology、Heart Rhythm Society、Institute of Electronics and Electrical Engineering，和American Institute for Medicine and Biology in Engineering。他也是Haemonetics Corporation的董事。
- Mark W. Kroll,retired in July 2005 from St. Jude Medical, Inc., where he held various executive level positions since 1995, most recently as Senior Vice President and Chief Technology Officer, Cardiac Rhythm Management Division. Dr. Kroll holds a B.S. in Mathematics and a M.S. and a Ph.D. from the Electrical Engineering department of the University of Minnesota and an M.B.A. from the University of St. Thomas. Dr. Kroll is also the named inventor of over 350 issued U.S. patents and is a Fellow of: American College of Cardiology, Heart Rhythm Society, Institute of Electronics and Electrical Engineering ("IEEE"), and the American Institute for Medicine and Biology in Engineering ("AIMBE"). Dr. Kroll has also served on the board of Haemonetics Corporation, provider of innovative medical technology solutions, since 2006.
- Michael J. Coyle
-
Michael J. Coyle， 2009年12月起，他担任Cardiac and Vascular Group的执行副总裁和集团总裁。在此之前，2001至2007年，他担任Cardiac Rhythm Management在圣裘德分公司的总裁；先前职位包括公司圣裘德Daig Catheter部门总裁和Eli Lilly & Company的多个领导职位。
Michael J. Coyle,joined Haemonetics Corporation Board in April 2020 and is a member of both the Audit Committee and the Technology Committee. Mr. Coyle previously served as the President and Chief Executive Officer of iRhythm Technologies, Inc., a digital healthcare company, from January 2021 to June 2021. From December 2009 to January 2021, Mr. Coyle served as Executive Vice President and Group President, Cardiac and Vascular Group of Medtronic plc (and its predecessor, Medtronic, Inc.), a global medical device company, where he oversaw four of the company's business divisions. Mr. Coyle previously served as President of the Cardiac Rhythm Management division at St. Jude Medical Inc. from 2001 to 2007 and earlier in his career held numerous leadership positions at St. Jude and Eli Lilly & Company. Mr. Coyle previously served on the boards of iRhythm Technologies, Inc. and of two NASDAQ-listed medical device companies responsible for making catheter-based products. He holds six U.S. patents related to cardiovascular medical device products and technologies. - Michael J. Coyle， 2009年12月起，他担任Cardiac and Vascular Group的执行副总裁和集团总裁。在此之前，2001至2007年，他担任Cardiac Rhythm Management在圣裘德分公司的总裁；先前职位包括公司圣裘德Daig Catheter部门总裁和Eli Lilly & Company的多个领导职位。
- Michael J. Coyle,joined Haemonetics Corporation Board in April 2020 and is a member of both the Audit Committee and the Technology Committee. Mr. Coyle previously served as the President and Chief Executive Officer of iRhythm Technologies, Inc., a digital healthcare company, from January 2021 to June 2021. From December 2009 to January 2021, Mr. Coyle served as Executive Vice President and Group President, Cardiac and Vascular Group of Medtronic plc (and its predecessor, Medtronic, Inc.), a global medical device company, where he oversaw four of the company's business divisions. Mr. Coyle previously served as President of the Cardiac Rhythm Management division at St. Jude Medical Inc. from 2001 to 2007 and earlier in his career held numerous leadership positions at St. Jude and Eli Lilly & Company. Mr. Coyle previously served on the boards of iRhythm Technologies, Inc. and of two NASDAQ-listed medical device companies responsible for making catheter-based products. He holds six U.S. patents related to cardiovascular medical device products and technologies.
高管简历
中英对照 | 中文 | 英文- James C. D'Arecca
James C. D'Arecca自2013年8月起担任此职位。在加入Allergan之前，他在Bausch + Lomb担任过类似的职位。 在加入Bausch + Lomb之前，D'Arecca先生曾在Merck＆Co.和先灵葆雅工作。 他还在普华永道会计师事务所担任了13年的注册会计师。 D'Arecca先生获得了哥伦比亚大学的MBA学位和他的学士学位。 在罗格斯大学会计学。
James C. D'Arecca was appointed Chief Accounting Officer - Global, on August 7 2013. Prior to joining Actavis, Mr. D'Arecca held a similar position at Bausch & Lomb. Prior to joining Bausch & Lomb, Mr. D'Arecca worked for Merck & Co., Inc. where he was Executive Director and Business Development Controller responsible for being the primary liaison between the Controller's organization and the business development and corporate licensing functions. Prior to joining Merck, Mr. D'Arecca was Executive Director and Assistant Controller at Schering-Plough. Mr. D'Arecca also spent 13 years with PricewaterhouseCoopers as a Certified Public Accountant. Mr. D'Arecca received his MBA from Columbia University and his BS in Accounting from Rutgers University.- James C. D'Arecca自2013年8月起担任此职位。在加入Allergan之前，他在Bausch + Lomb担任过类似的职位。 在加入Bausch + Lomb之前，D'Arecca先生曾在Merck＆Co.和先灵葆雅工作。 他还在普华永道会计师事务所担任了13年的注册会计师。 D'Arecca先生获得了哥伦比亚大学的MBA学位和他的学士学位。 在罗格斯大学会计学。
- James C. D'Arecca was appointed Chief Accounting Officer - Global, on August 7 2013. Prior to joining Actavis, Mr. D'Arecca held a similar position at Bausch & Lomb. Prior to joining Bausch & Lomb, Mr. D'Arecca worked for Merck & Co., Inc. where he was Executive Director and Business Development Controller responsible for being the primary liaison between the Controller's organization and the business development and corporate licensing functions. Prior to joining Merck, Mr. D'Arecca was Executive Director and Assistant Controller at Schering-Plough. Mr. D'Arecca also spent 13 years with PricewaterhouseCoopers as a Certified Public Accountant. Mr. D'Arecca received his MBA from Columbia University and his BS in Accounting from Rutgers University.
- Christopher Simon
Christopher Simon，担任总裁兼首席执行官，于2016年5月加入Haemonetics公司。他此前曾担任McKinsey & Company的高级合伙人，从事全球医疗产品实践。他曾担任McKinsey & Company的顾问（1993年以来），最近担任McKinsey & Company与Haemonetics的战略回顾的领导合伙人。此前，他曾担任Baxter Healthcare Corporation的商业职务。
Christopher Simon,is President and Chief Executive Officer of Haemonetics Corporation. He joined Haemonetics in May 2016 and Haemonetics Corporation Board in September 2016. Mr. Simon previously served as a Senior Partner of McKinsey & Company where he led the Global Medical Products Practice. Mr. Simon served as a consultant with McKinsey & Company beginning in 1993 and was the lead partner for McKinsey & Company's strategy review with Haemonetics that began in October 2015, where he gained invaluable insights into the Company's business and markets. Prior to his career at McKinsey & Company, Mr. Simon served in commercial roles with Baxter Healthcare Corporation and as a U.S. Army Infantry Officer in Korea with the 1st Ranger Battalion. He also currently serves on the Board of Directors of AdvaMed, a global trade association of companies that develop, produce, manufacture and market medical technologies. Mr. Simon earned a Bachelor of Science in Economics from the Wharton School at the University of Pennsylvania and an M.B.A. from Harvard Business School.- Christopher Simon，担任总裁兼首席执行官，于2016年5月加入Haemonetics公司。他此前曾担任McKinsey & Company的高级合伙人，从事全球医疗产品实践。他曾担任McKinsey & Company的顾问（1993年以来），最近担任McKinsey & Company与Haemonetics的战略回顾的领导合伙人。此前，他曾担任Baxter Healthcare Corporation的商业职务。
- Christopher Simon,is President and Chief Executive Officer of Haemonetics Corporation. He joined Haemonetics in May 2016 and Haemonetics Corporation Board in September 2016. Mr. Simon previously served as a Senior Partner of McKinsey & Company where he led the Global Medical Products Practice. Mr. Simon served as a consultant with McKinsey & Company beginning in 1993 and was the lead partner for McKinsey & Company's strategy review with Haemonetics that began in October 2015, where he gained invaluable insights into the Company's business and markets. Prior to his career at McKinsey & Company, Mr. Simon served in commercial roles with Baxter Healthcare Corporation and as a U.S. Army Infantry Officer in Korea with the 1st Ranger Battalion. He also currently serves on the Board of Directors of AdvaMed, a global trade association of companies that develop, produce, manufacture and market medical technologies. Mr. Simon earned a Bachelor of Science in Economics from the Wharton School at the University of Pennsylvania and an M.B.A. from Harvard Business School.
- Michelle Basil
Michelle Basil，于2017年3月加入公司，担任执行Vice President，总法律顾问。Basil女士曾于1997年9月至2017年3月担任波士顿律师事务所Nutter，McClennen&Fish LLP的生命科学实践组合伙人兼主席。Basil女士的实践专注于公司法和证券法，包括并购，战略合作伙伴关系和公司治理事务，并代表上市和私营公司，主要是在生命科学和医疗技术行业。Basil女士是马萨诸塞州医疗器械工业委员会（MassMedic）的董事会成员。她获得马萨诸塞州的律师资格，持有加州大学伯克利分校（the University of California at Berkeley）的文学学士学位和法学博士学位。
Michelle Basil,joined the Company in March 2017 as Executive Vice President, General Counsel. Ms. Basil was previously a Partner and Chair of the Life Sciences Practice Group at Nutter, McClennen & Fish LLP, a Boston-based law firm, where she practiced from September 1997 to March 2017. Ms. Basil focused her practice on corporate and securities law, including mergers and acquisitions, strategic partnerships and corporate governance matters, and represented both public and private companies, principally in the life sciences and medical technology industries. Ms. Basil is a member of the Board of Directors of the Massachusetts Medical Device Industry Council (MassMEDIC). She is admitted to the bar in Massachusetts and holds both a Bachelor of Arts and a Juris Doctor from the University of California at Berkeley.- Michelle Basil，于2017年3月加入公司，担任执行Vice President，总法律顾问。Basil女士曾于1997年9月至2017年3月担任波士顿律师事务所Nutter，McClennen&Fish LLP的生命科学实践组合伙人兼主席。Basil女士的实践专注于公司法和证券法，包括并购，战略合作伙伴关系和公司治理事务，并代表上市和私营公司，主要是在生命科学和医疗技术行业。Basil女士是马萨诸塞州医疗器械工业委员会（MassMedic）的董事会成员。她获得马萨诸塞州的律师资格，持有加州大学伯克利分校（the University of California at Berkeley）的文学学士学位和法学博士学位。
- Michelle Basil,joined the Company in March 2017 as Executive Vice President, General Counsel. Ms. Basil was previously a Partner and Chair of the Life Sciences Practice Group at Nutter, McClennen & Fish LLP, a Boston-based law firm, where she practiced from September 1997 to March 2017. Ms. Basil focused her practice on corporate and securities law, including mergers and acquisitions, strategic partnerships and corporate governance matters, and represented both public and private companies, principally in the life sciences and medical technology industries. Ms. Basil is a member of the Board of Directors of the Massachusetts Medical Device Industry Council (MassMEDIC). She is admitted to the bar in Massachusetts and holds both a Bachelor of Arts and a Juris Doctor from the University of California at Berkeley.
- Anila Lingamneni
Anila Lingamneni于2020年4月加入公司，担任执行副总裁兼首席技术官。加入公司之前，Lingamneni女士于2017年2月至2020年3月担任Baxter International肾脏研发副总裁，负责为透析患者提供肾脏治疗解决方案的产品组合，包括设备，软件，一次性用品和液体。在此职位上，她领导了一个全球分布的工程师和科学家团队，以推动长期产品路线图定义和治疗创新，并推出了关键产品。2013年5月至2017年1月，Lingamneni女士还担任百特国际设备工程副总裁，负责百特医疗设备组合的所有机电设备和软件应用，包括输液系统，复合系统，肾腹膜和血液透析系统以及急性肾疗法系统。在加入Baxter之前，Lingamneni女士在通用电气医疗保健担任过多个职位，包括X射线诊断成像业务部门的首席技术官。Lingamneni女士获得了印度Birla理工学院的电气和电子工程学士学位以及数学硕士学位，并获得了爱荷华州州立大学的生物医学工程理学硕士学位。
Anila Lingamneni,joined the Company as Executive Vice President, Chief Technology Officer in April 2020. Prior to joining the Company, Ms. Lingamneni served as Vice President, Renal R&D at Baxter International from February 2017 to March 2020, where she was responsible for the product portfolio delivering renal therapy solutions to dialysis patients, including devices, software, disposables and fluids. In this role, she led a globally distributed team of engineers and scientists to drive long-term product roadmap definition and therapy innovation and delivered critical product launches. From May 2013 to January 2017, Ms. Lingamneni also served as Vice President, Device Engineering at Baxter International, where she was responsible for all electromechanical devices and software applications for Baxter's medical device portfolio, including infusion systems, compounding systems, renal peritoneal and hemodialysis systems and acute renal therapy systems. Before joining Baxter, Ms. Lingamneni held several roles at General Electric Healthcare, including Chief Technology Officer of the X-Ray Diagnostic Imaging Business Unit. Ms. Lingamneni received a Bachelor of Science in Electrical and Electronics Engineering and a Master of Science in Mathematics from Birla Institute of Technology and Science in India, and she earned a Master of Science degree in Biomedical Engineering from Iowa State University.- Anila Lingamneni于2020年4月加入公司，担任执行副总裁兼首席技术官。加入公司之前，Lingamneni女士于2017年2月至2020年3月担任Baxter International肾脏研发副总裁，负责为透析患者提供肾脏治疗解决方案的产品组合，包括设备，软件，一次性用品和液体。在此职位上，她领导了一个全球分布的工程师和科学家团队，以推动长期产品路线图定义和治疗创新，并推出了关键产品。2013年5月至2017年1月，Lingamneni女士还担任百特国际设备工程副总裁，负责百特医疗设备组合的所有机电设备和软件应用，包括输液系统，复合系统，肾腹膜和血液透析系统以及急性肾疗法系统。在加入Baxter之前，Lingamneni女士在通用电气医疗保健担任过多个职位，包括X射线诊断成像业务部门的首席技术官。Lingamneni女士获得了印度Birla理工学院的电气和电子工程学士学位以及数学硕士学位，并获得了爱荷华州州立大学的生物医学工程理学硕士学位。
- Anila Lingamneni,joined the Company as Executive Vice President, Chief Technology Officer in April 2020. Prior to joining the Company, Ms. Lingamneni served as Vice President, Renal R&D at Baxter International from February 2017 to March 2020, where she was responsible for the product portfolio delivering renal therapy solutions to dialysis patients, including devices, software, disposables and fluids. In this role, she led a globally distributed team of engineers and scientists to drive long-term product roadmap definition and therapy innovation and delivered critical product launches. From May 2013 to January 2017, Ms. Lingamneni also served as Vice President, Device Engineering at Baxter International, where she was responsible for all electromechanical devices and software applications for Baxter's medical device portfolio, including infusion systems, compounding systems, renal peritoneal and hemodialysis systems and acute renal therapy systems. Before joining Baxter, Ms. Lingamneni held several roles at General Electric Healthcare, including Chief Technology Officer of the X-Ray Diagnostic Imaging Business Unit. Ms. Lingamneni received a Bachelor of Science in Electrical and Electronics Engineering and a Master of Science in Mathematics from Birla Institute of Technology and Science in India, and she earned a Master of Science degree in Biomedical Engineering from Iowa State University.
- Josep L. Llorens
Josep L.Llorens于2018年8月加入公司担任全球制造和供应链高级副总裁。Llorens先生拥有30多年的经验，领导全球医疗保健和消费者业务在一次性用品，资本设备，设备和软件方面的众多转变。加入公司之前，他曾担任Philips公司的多种运营和供应链职务，不断增加诊断和治疗、患者监测和心脏护理业务的责任，他于1992年加入该公司，最近担任高级副总裁，从2018年1月至2018年8月，飞利浦医疗保健诊断成像的产业战略和先进制造工程领导者。Llorens先生获得了巴塞罗那大学的工商管理学士学位和巴塞罗那加泰罗尼亚理工大学的电信工程硕士学位。他还拥有麻省理工学院斯隆管理学院的技术，运营和价值链管理执行证书。
Josep L. Llorens,joined the Company as Senior Vice President, Global Manufacturing and Supply Chain in August 2018 and was promoted to Executive Vice President, Global Manufacturing and Supply Chain in July 2021. Prior to joining the Company, Mr. Llorens held various operations and supply chain roles of increasing responsibility within the diagnostics and treatment, patient monitoring and cardiac care business of Philips, which he joined in 1992, most recently serving as Senior Vice President, Industrial Strategy and Advanced Manufacturing Engineering Leader for Philips Healthcare Diagnostic Imaging from January 2018 to August 2018. Mr. Llorens received a bachelor's degree in Business Administration from the University of Barcelona and a master's degree in Telecommunications Engineering from the Polytechnic University of Catalonia in Barcelona. He also holds an Executive Certificate in Technology, Operations and Value Chain Management from the MIT Sloan School of Management.- Josep L.Llorens于2018年8月加入公司担任全球制造和供应链高级副总裁。Llorens先生拥有30多年的经验，领导全球医疗保健和消费者业务在一次性用品，资本设备，设备和软件方面的众多转变。加入公司之前，他曾担任Philips公司的多种运营和供应链职务，不断增加诊断和治疗、患者监测和心脏护理业务的责任，他于1992年加入该公司，最近担任高级副总裁，从2018年1月至2018年8月，飞利浦医疗保健诊断成像的产业战略和先进制造工程领导者。Llorens先生获得了巴塞罗那大学的工商管理学士学位和巴塞罗那加泰罗尼亚理工大学的电信工程硕士学位。他还拥有麻省理工学院斯隆管理学院的技术，运营和价值链管理执行证书。
- Josep L. Llorens,joined the Company as Senior Vice President, Global Manufacturing and Supply Chain in August 2018 and was promoted to Executive Vice President, Global Manufacturing and Supply Chain in July 2021. Prior to joining the Company, Mr. Llorens held various operations and supply chain roles of increasing responsibility within the diagnostics and treatment, patient monitoring and cardiac care business of Philips, which he joined in 1992, most recently serving as Senior Vice President, Industrial Strategy and Advanced Manufacturing Engineering Leader for Philips Healthcare Diagnostic Imaging from January 2018 to August 2018. Mr. Llorens received a bachelor's degree in Business Administration from the University of Barcelona and a master's degree in Telecommunications Engineering from the Polytechnic University of Catalonia in Barcelona. He also holds an Executive Certificate in Technology, Operations and Value Chain Management from the MIT Sloan School of Management.
- Roy Galvin
Roy Galvin，2022年10月加入Haemonetics，担任全球血浆和血液中心总裁。他负责Haemonetics公司的血浆和血液中心业务，通过收集和捐赠管理解决方案提升公司的领导地位和创新。高尔文先生在全球医疗保健技术领域的丰富经验包括在美敦力公司工作超过25年，他担任的领导职务包括美国颅骨和脊柱技术业务高级副总裁，以及修复治疗集团美洲业务高级副总裁、美国外科技术销售副总裁和神经技术全球营销总监。在职业生涯早期，高尔文先生在Xomed Surgical Products Inc.（在被美敦力收购之前）、Corin Orthopedics、Biomet Corporation，Inc.和Zimmer Orthopedic Inc.担任越来越重要的职务。高尔文先生毕业于朴茨茅斯理工学院。
Roy Galvin,joined Haemonetics in October 2022 as President, Global Plasma and Blood Center. He is responsible for Haemonetics' Plasma and Blood Center businesses, advancing the Company's leadership positions and innovation through its collection and donor management solutions. Mr. Galvin's significant experience in global healthcare technology includes more than 25 years at Medtronic plc, where his leadership roles included Senior Vice President Commercial – US Cranial & Spinal Technologies, as well as positions as Senior Vice President Commercial Americas – Restorative Therapy Group, Vice President US Sales – Surgical Technologies, and Director of Global Marketing – Neurologic Technologies. Earlier in his career, Mr. Galvin held positions of increasing responsibility at Xomed Surgical Products Inc. (prior to its acquisition by Medtronic), Corin Orthopedics, Biomet Corporation, Inc. and Zimmer Orthopedic Inc. Mr. Galvin is a graduate of Portsmouth Polytechnic.- Roy Galvin，2022年10月加入Haemonetics，担任全球血浆和血液中心总裁。他负责Haemonetics公司的血浆和血液中心业务，通过收集和捐赠管理解决方案提升公司的领导地位和创新。高尔文先生在全球医疗保健技术领域的丰富经验包括在美敦力公司工作超过25年，他担任的领导职务包括美国颅骨和脊柱技术业务高级副总裁，以及修复治疗集团美洲业务高级副总裁、美国外科技术销售副总裁和神经技术全球营销总监。在职业生涯早期，高尔文先生在Xomed Surgical Products Inc.（在被美敦力收购之前）、Corin Orthopedics、Biomet Corporation，Inc.和Zimmer Orthopedic Inc.担任越来越重要的职务。高尔文先生毕业于朴茨茅斯理工学院。
- Roy Galvin,joined Haemonetics in October 2022 as President, Global Plasma and Blood Center. He is responsible for Haemonetics' Plasma and Blood Center businesses, advancing the Company's leadership positions and innovation through its collection and donor management solutions. Mr. Galvin's significant experience in global healthcare technology includes more than 25 years at Medtronic plc, where his leadership roles included Senior Vice President Commercial – US Cranial & Spinal Technologies, as well as positions as Senior Vice President Commercial Americas – Restorative Therapy Group, Vice President US Sales – Surgical Technologies, and Director of Global Marketing – Neurologic Technologies. Earlier in his career, Mr. Galvin held positions of increasing responsibility at Xomed Surgical Products Inc. (prior to its acquisition by Medtronic), Corin Orthopedics, Biomet Corporation, Inc. and Zimmer Orthopedic Inc. Mr. Galvin is a graduate of Portsmouth Polytechnic.
- Laurie A. Miller
Laurie A. Miller于2021年8月晋升为Haemonetics高级副总裁兼首席人力资源官。米勒女士于2016年加入Haemonetics，之前担任人力资源副总裁兼人力资源和人才管理高级总监，帮助公司建立以绩效为导向的协作文化，指导以员工为中心的关键举措，并为员工创造一个强大的工作环境。在加入Haemonetics公司之前，米勒女士在企业信息管理公司铁山公司担任越来越重要的职务，包括在2010年2月至2016年4月担任人力资源总监。在职业生涯的早期，米勒女士曾在全球快餐店特许经营商唐恩都乐和建筑管理公司Shawmut Design and Construction担任多个人力资源职位，职责广泛且日益增加。米勒女士在韦斯特菲尔德州立学院获得了商业管理学士学位，在伊曼纽尔学院获得了管理学硕士学位。
Laurie A. Miller,was promoted to Senior Vice President, Chief Human Resources Officer of Haemonetics in August 2021. Ms. Miller joined Haemonetics in 2016 and previously held positions as Vice President, Human Resources and Senior Director, Human Resources and Talent Management, where she helped build the Company's collaborative, performance-driven culture, direct key employee-focused initiatives and create a strong workplace environment for employees. Prior to joining Haemonetics, Ms. Miller served in positions of increasing responsibility at Iron Mountain Inc., an enterprise information management company, including as Director of Human Resources, from February 2010 to April 2016. Earlier in her career, Ms. Miller held various Human Resources positions of broad and increasing responsibility at Dunkin' Brands Group Inc., a global franchisor of quick service restaurants, and Shawmut Design and Construction, a construction management firm. Ms. Miller earned a Bachelor of Science in Business Management from Westfield State College and a Master of Science in Management from Emmanuel College.- Laurie A. Miller于2021年8月晋升为Haemonetics高级副总裁兼首席人力资源官。米勒女士于2016年加入Haemonetics，之前担任人力资源副总裁兼人力资源和人才管理高级总监，帮助公司建立以绩效为导向的协作文化，指导以员工为中心的关键举措，并为员工创造一个强大的工作环境。在加入Haemonetics公司之前，米勒女士在企业信息管理公司铁山公司担任越来越重要的职务，包括在2010年2月至2016年4月担任人力资源总监。在职业生涯的早期，米勒女士曾在全球快餐店特许经营商唐恩都乐和建筑管理公司Shawmut Design and Construction担任多个人力资源职位，职责广泛且日益增加。米勒女士在韦斯特菲尔德州立学院获得了商业管理学士学位，在伊曼纽尔学院获得了管理学硕士学位。
- Laurie A. Miller,was promoted to Senior Vice President, Chief Human Resources Officer of Haemonetics in August 2021. Ms. Miller joined Haemonetics in 2016 and previously held positions as Vice President, Human Resources and Senior Director, Human Resources and Talent Management, where she helped build the Company's collaborative, performance-driven culture, direct key employee-focused initiatives and create a strong workplace environment for employees. Prior to joining Haemonetics, Ms. Miller served in positions of increasing responsibility at Iron Mountain Inc., an enterprise information management company, including as Director of Human Resources, from February 2010 to April 2016. Earlier in her career, Ms. Miller held various Human Resources positions of broad and increasing responsibility at Dunkin' Brands Group Inc., a global franchisor of quick service restaurants, and Shawmut Design and Construction, a construction management firm. Ms. Miller earned a Bachelor of Science in Business Management from Westfield State College and a Master of Science in Management from Emmanuel College.
- Stewart W. Strong
Stewart W. Strong,2019年9月加入公司，担任全球医院院长。2017年2月至2019年9月，Strong先生在全球医疗公司Teleflex Incorporated担任介入产品业务总裁兼总经理，除其他职责外，他通过有机增长机会和战略收购，领导公司介入心脏病业务的扩张。Strong先生还曾在2013年12月至2017年2月期间担任泰利福北美销售、血管通路副总裁和心脏护理全球副总裁兼总经理。在加入泰利福之前，斯特朗曾在多家医疗技术公司担任领导职务，包括Vidacare公司的销售副总裁（在2013年被泰利福收购之前），以及在AtriCure公司、美敦力公司的心脏瓣膜部门和强生公司的Ethicon内外科部门担任越来越重要的职务。Strong先生拥有康涅狄格大学的文学学士学位。
Stewart W. Strong,joined the Company as President, Global Hospital in September 2019. From February 2017 to September 2019, Mr. Strong served as President and General Manager of the interventional products business at Teleflex Incorporated, a global medical company, where he, among other responsibilities, led the expansion of the company's interventional cardiology business through organic growth opportunities and strategic acquisitions. Mr. Strong also served as Vice President of North America Sales, Vascular Access and Global Vice President and General Manger, Cardiac Care at Teleflex between December 2013 and February 2017. Before joining Teleflex, Mr. Strong held leadership roles with several medical technology companies, including Vice President of Sales at Vidacare Corporation (prior to its acquisition by Teleflex in 2013) and positions of increasing responsibility at AtriCure, Inc., Medtronic plc's heart valve division, and Johnson & Johnson's ethicon endo-surgery division. Mr. Strong holds a Bachelor of Arts from the University of Connecticut.- Stewart W. Strong,2019年9月加入公司，担任全球医院院长。2017年2月至2019年9月，Strong先生在全球医疗公司Teleflex Incorporated担任介入产品业务总裁兼总经理，除其他职责外，他通过有机增长机会和战略收购，领导公司介入心脏病业务的扩张。Strong先生还曾在2013年12月至2017年2月期间担任泰利福北美销售、血管通路副总裁和心脏护理全球副总裁兼总经理。在加入泰利福之前，斯特朗曾在多家医疗技术公司担任领导职务，包括Vidacare公司的销售副总裁（在2013年被泰利福收购之前），以及在AtriCure公司、美敦力公司的心脏瓣膜部门和强生公司的Ethicon内外科部门担任越来越重要的职务。Strong先生拥有康涅狄格大学的文学学士学位。
- Stewart W. Strong,joined the Company as President, Global Hospital in September 2019. From February 2017 to September 2019, Mr. Strong served as President and General Manager of the interventional products business at Teleflex Incorporated, a global medical company, where he, among other responsibilities, led the expansion of the company's interventional cardiology business through organic growth opportunities and strategic acquisitions. Mr. Strong also served as Vice President of North America Sales, Vascular Access and Global Vice President and General Manger, Cardiac Care at Teleflex between December 2013 and February 2017. Before joining Teleflex, Mr. Strong held leadership roles with several medical technology companies, including Vice President of Sales at Vidacare Corporation (prior to its acquisition by Teleflex in 2013) and positions of increasing responsibility at AtriCure, Inc., Medtronic plc's heart valve division, and Johnson & Johnson's ethicon endo-surgery division. Mr. Strong holds a Bachelor of Arts from the University of Connecticut.